【摘要】 目的 :评价交替半身照射 (AHBI)治疗急性淋巴细胞白血病(ALL)的疗效。方法:采用AHBI治疗11例ALL患者。先给予大剂量化疗 ,然后分别对上、下半身照射6～9Gy。上半身照射在停大剂量化疗15(13～19)d进行 ,上、下半身照射间隔25(13～37)d。选择同期行自体造血干细胞移植 (AHSCT)的14例ALL患者作为对照组。结果:AHBI治疗的患者均获得造血恢复 ,3年无病生存率(47.73±17.55) % ,中位随访时间为803.5(428～1446)d ,治疗相关死亡率为0 ,治疗经费 (8.3±4.8)万元。AHSCT组3年无病生存率为(53.88±14.08) % ,中位随访时间为512(176～1606)d ,移植相关死亡率为14 % ,治疗经费 (19.5±11.0)万元。2组ALL患者3年无病生存率差别无统计学意义 (P>0.05)。AHBI治疗费用明显低于AHSCT治疗 (P<0.05)。结论:交替半身照射治疗可作为ALL的一种有效治疗手段 ,具有疗效好 ,费用低 ,治疗程序简单、并发症少等优点。更多还原

【Abstract】 Objective:To assess the role of alternative hemi-body irradiation (AHBI) in patients with acute lymphoblastic leukemia(ALL).Methods: Eleven patients with ALL received two-step AHBI on day 15 (13～19) following high-dose chemotherapy. Upper hemi-body irradiation (UHBI) and lower hemi-body irradiation (LHBI) were sequentially given as a single dose of 6～9 Gy at an interval of 25 (13～37) days. Fourteen recipients of autologous hematopoietic stem cell transplantation(AHSCT) during the same period were chosen as the controls.Results: Hematopoietic reconstitutions were observed in all AHBI recipients.The 3 year disease free survival(DFS) rate and the cumulative incidence of AHBI related mortality in patients having received AHBI were (47.73±17.55)%and 0,respectively.The median follow-up period was 803.5 (428～1 446) days. The 3 year DFS and the cumulative incidence of AHSCT related mortality in 14 ALL patients in the AHSCT group were(53.88±14.08)%and 14%,respectively. There was no significant difference in 3 year DFS between AHBI recipients and AHSCT recipients with ALL in this two groups(P>0.05).Conclusion: AHBI provided a feasible approach for ALL.This strategy has several advantages which include desirable effectiveness, low costs, practical operation, and acceptable side effects.更多还原